Black Diamond Therapeutics, Inc. (BDTX)
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2020
- $0
- Net income
- $22.4M
- Total assets
- $143.0M
- Market cap
- $112.9M
- Operating margin
- 17.9%
- Net margin
- 32.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $70.0M
- Operating expenses
- $57.5M
- Operating income
- $12.5M
- Income tax
- $0
- Net income
- $22.4M
- EPS (basic)
- $0.39
- EPS (diluted)
- $0.39
Balance sheet
- Total assets
- $143.0M
- Current assets
- $132.4M
- Total liabilities
- $30.8M
- Current liabilities
- $15.7M
- Shareholders’ equity
- $112.2M
Cash flow
- Operating cash flow
- $29.6M
- Investing cash flow
- -$44.9M
- Financing cash flow
- -$146.0K
- Net cash flow
- -$15.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $112.9M
- P/E ratio
- 4.5
- EPS (diluted)
- $0.39
- Shares outstanding
- 64.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 30, 2020
Black Diamond Therapeutics, Inc. (BDTX) Stock Price
- Profitable — net income of $22.4M in FY2020.
- Trading 64% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Black Diamond Therapeutics, Inc..
Write a review
News about Black Diamond Therapeutics, Inc.
News & sentiment via Polygon.io
Black Diamond Therapeutics, Inc.: frequently asked questions
Is Black Diamond Therapeutics, Inc. an American company?
Black Diamond Therapeutics, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Black Diamond Therapeutics, Inc. headquartered?
Black Diamond Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Black Diamond Therapeutics, Inc. publicly traded?
Yes — Black Diamond Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol BDTX on the NASDAQ.
What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
